Background: With rising cancer care costs, including high-priced cancer drugs, financial hardship is increasingly documented among cancer survivors in the United States; research findings have not been synthesized. Methods: We conducted a systematic review of articles published between 1990 and 2015 describing the financial hardship experienced by cancer survivors using PubMed, Embase, Scopus, and CINAHL databases. We categorized measures of financial hardship into: material conditions (eg, out-of-pocket costs, productivity loss, medical debt, or bankruptcy), psychological responses (eg, distress or worry), and coping behaviors (eg, skipped medications). We abstracted findings and conducted a qualitative synthesis. Results: Among 676 studies identified, 45 met the inclusion criteria and were incorporated in the review. The majority of the studies (82%, n ¼ 37) reported financial hardship as a material condition measure; others reported psychological (7%, n ¼ 3) and behavioral measures (16%, n ¼ 7). Financial hardship measures were heterogeneous within each broad category, and the prevalence of financial hardship varied by the measure used and population studied. Mean annual productivity loss ranged from $380 to $8236, 12% to 62% of survivors reported being in debt because of their treatment, 47% to 49% of survivors reported experiencing some form of financial distress, and 4% to 45% of survivors did not adhere to recommended prescription medication because of cost. Conclusions: Financial hardship is common among cancer survivors, although we found substantial heterogeneity in its prevalence. Our findings highlight the need for consistent use of definitions, terms, and measures to determine the best intervention targets and inform intervention development in order to prevent and minimize the impact of financial hardship experienced by cancer survivors.
cancer survivors, even after controlling for socioeconomic and clinical characteristics (15) . The mechanism for this increased mortality risk is not entirely clear. Poorer quality of life and overall well-being, increased stress, restricted choices associated with limited resources (eg, food and housing insecurity), and decreased treatment adherence are among the hypothesized mechanisms (15, 16) .
Increasingly, researchers have documented the prevalence of different aspects of financial hardships among cancer survivors (17, 18) . A prior review highlighted the heterogeneity in measures of financial hardship in cancer survivorship research (19) ; however, that review focused exclusively on terminal cancer patients and only included studies published through 2006. Little research has been conducted to synthesize findings from these studies across the cancer care continuum. In an effort to build on existing research and close this gap, we conducted a systematic review of the published literature guided by a financial hardship typology to inform future research in cancer survivorship and intervention development in order to minimize the effects of financial hardship.
Methods

Financial Hardship Typology
Building on theoretical work in health disparities research (16, 20, 21) , we developed a typology for conceptualizing financial hardship in cancer survivors (22) . Previous research has shown material (23) , psychological (24) , and behavioral (25) aspects of the financial hardship experience among cancer patients, and recent studies have begun to differentiate the multiple domains of financial hardship (18) , thus heeding the calls in the literature for greater conceptual clarity to inform both financial hardship measurement and intervention development for cancer survivors (22, 26) . As described in Figure 1 , financial hardship can be characterized as: 1) the material conditions that arise from the increased OOP expenses and lower income that can result from the inability to work during/following cancer treatment, 2) the psychological response to the increase in household expenses that must now be managed as patients navigate cancer care, or 3) the coping behaviors that patients adopt to manage their medical care while experiencing increased household expenses during/following cancer care. We used this typology to guide our literature search, abstract data from identified studies, and synthesize results from the underlying studies.
As indicated in Figure 1 , there may be some overlap across these domains of the underlying multidimensional construct of financial hardship; while the psychological response measures may be clearly distinct from the other two domains, the material conditions and coping behavior measures may seem more similar. However, we contend that there is not complete overlap among the material conditions and coping behavior domains in our typology. Full overlap between these two domains would suggest perfect correlation between material conditions measures and coping behavior measures. The distinction in our typology between material conditions measures and coping behavior measures is that the former attempts to capture the financial costs of cancer care to the patient and/or the depletion of financial resources as a result of cancer care; however, the latter attempts to capture the purposeful effort (27) used by the patient to manage the financial situation produced by the reduction of financial resources. The purposeful efforts or actions to economize that are used to manage the depletion of financial resources distinguish the coping behavior domain from the other domains. Though our typology does not include a temporal aspect, the coping behavior (eg, economizing strategies such as taking less medication and/or forgoing care because of cost) measures are assumed to capture the patient's behavioral response to the reduction in material conditions and the stressful psychological response caused by the substantial financial burden of cancer care.
Literature Search
We used the PubMed, Embase, Scopus, and CINAHL databases to identify articles describing the financial burden of cancer arise from the increased out-of-pocket expenses and potentially lower income that results from the inability to work during/following cancer treatment; the psychological response to the increase in household expenses that must now be managed as patients navigate cancer care; and the coping behaviors that patients adopt to manage their medical care while experiencing increased household expenses during/following cancer care.
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that were written in English and published between January 1, 1990, and December 31, 2015. In the PubMed database, the search strategy used a combination of the Medical Subject Heading (MeSH) terms "cost of illness," "healthcare costs," "health expenditures," and "neoplasm," and related keywords (ie, bankruptcy, debt, OOP, mortality cost, cancer, economic burden, economic hardship, financial burden, financial hardship, financial stress, financial distress, material hardship, and financial toxicity). These terms also reflect concepts in the costeffectiveness literature. We replicated the search strategy in the Embase, Scopus, and CINAHL databases according to their search parameters. The combined searches from all four databases yielded 676 unique articles (Supplementary Methods and  Supplementary Table 1 , available online).
Articles were excluded if the study was conducted outside of the United States (n ¼ 239) because of important differences in health care systems, including the absence of universal health insurance coverage and the potential for very high patient OOP costs in the United States compared with other developed countries. Editorials, commentaries, and literature reviews were excluded (n ¼ 381). Articles were also required to include some aspect of the financial hardship of cancer, present results from quantitative data analysis, and include individual-level data for at least 10 survivors. Articles describing a specific treatment or procedure (eg, economic burden of repeat renal surgery) were also excluded. The abstracts from the remaining 35 articles were selected for full text review. Reference lists were also reviewed, and 10 additional articles were identified for inclusion. A total of 45 articles were included in the literature review (6) (7) (8) (9) (10) 12, 14, 23, (Supplementary Figure 1 , available online).
Data Abstraction
Data were abstracted on study characteristics, cancer patient characteristics, and measures of financial hardship from each article. Study characteristics included data source, geographic setting, service type, payer type, indirect cost, study design, and comparison group. Data on cancer patient characteristics included method of identification (eg, registry, self-report), sample size, age, stage, and cancer site. We grouped measures of financial hardship into the three categories defined in our typology in Figure 1 : material conditions, psychological responses, and coping behaviors. Material conditions included measures of OOP costs, indirect costs, and productivity loss (ie, the loss of economic resources and opportunities associated with morbidity because of cancer and its treatment), medical debt, and bankruptcy experienced by cancer survivors. Psychological responses were measured as any psychological, emotional, and social impact experienced by cancer survivors because of financial hardship (eg, feeling of distress because of costs of cancer care; concern about wages/income meeting expenses related to costs of cancer care). Coping behavior measures included assessments of treatment nonadherence and forgoing medical care because of cost. Some studies used composite or summary measures across multiple domains of financial hardship, which we grouped separately.
A single author reviewed abstracts for objective information (eg, conducted in United States, included cancer survivors), and three of the authors collectively made decisions about whether studies should be included or excluded. A single author abstracted data from the underlying studies, and three authors reviewed these data. Any disagreements were resolved by consensus.
Results
Study Characteristics
Over half of the studies (58%, n ¼ 26) were published in 2013, 2014, and 2015 ( Figure 2) . The majority of studies were conducted using national (47%, n ¼ 21) or multistate-level data (29%, n ¼ 13) (Table 1) , while others used data from a single institute/city (20%, n ¼ 9) or single state (4%, n ¼ 2). Studies used data from a variety of sources, including the Medical Expenditures Panel Survey (MEPS; 22%, n ¼ 10) and the linked Surveillance, Epidemiology, and End Results Program (SEER)-Medicare data (16%, n ¼ 7). Most studies featured cross-sectional (64%, n ¼ 29) or cohort (29%, n ¼ 13) designs. Many studies included comparison groups comprised of noncancer controls (38%, n ¼ 17) or other defined groups (ie, patients with chronic heart disease; 16%, n ¼ 7); however, 47% (n ¼ 21) of the studies did not include a comparison group. Study populations included newly diagnosed patients in the initial/treatment phase (58%, n ¼ 26) with few studies specifically addressing end of life/last year of life (4%, n ¼ 2). Cancer survivors were identified by self-report (33%, n ¼ 15), medical record review (27%, n ¼ 12), registry (18%, n ¼ 8), and insurance claims (11%, n ¼ 5) (Table 1 ). Approximately half of the studies included patients at all stages of disease at diagnosis (49%, n ¼ 22), whereas 20% (n ¼ 9) included stages I-III and 31% (n ¼ 14) of studies did not list study patients' stage of cancer. The most common cancer sites reported were breast (42%, n ¼ 19), colon (38%, n ¼ 17), lung (24%, n ¼ 11), prostate (20%, n ¼ 9), uterine (11%, n ¼ 5), and ovarian (9%, n ¼ 4). Over a third of the studies included all cancer sites (36%, n ¼ 16).
Measures of Financial Hardship of Cancer
Across studies, there was a large degree of inconsistency in the terms used, including financial distress, financial stress, financial hardship, financial problem, financial toxicity, financial burden, economic burden, economic hardship, and financial impact. The majority of studies reported material condition measures (82%, n ¼ 37), and there was considerable variation in the measures, including direct medical costs or OOP costs (44%, n ¼ 20), indirect cost or cost because of productivity loss (40%, n=18), medical debt/depletion of assets (27%, n ¼ 12), healthrelated spending as a percentage of total household income (ie, >20% of income) (9%, n ¼ 4), decline in financial status (7%, n ¼ 3), patient time costs (7%, n ¼ 3), and bankruptcy (7%, n ¼ 3) (Table 1 ). Approximately 7% (n ¼ 3) of the studies reported financial hardship as a psychological response measure (ie, assess subjective financial distress, stress and worry in survivors), while a total of 16% (n ¼ 7) of studies reported financial hardship as a coping behavior measure, evaluating the association between cancer-related expenses and utilization of medical care services (ie, skipped treatment appointments or filled only part of a medication prescription). Thirteen studies (29%) reported financial hardship using composite or other summary measures. Few studies included in our review used validated measures or commented about the validation process for financial hardship measures; a single study (43) included the comprehensive score for financial toxicity (COST) measure developed specifically as a patient-reported outcome in oncology care (20) , and three studies (10, 44, 50) used the InCharge Financial Distress/ Financial Well-Being Scale (IFDFW), which was tested for validity and reliability but is not health care specific (65) . Both the COST measure and the IFDFW scales include aspects of material and psychological hardship.
Even objective measures that addressed the same basic financial hardship concept were inconsistently reported across studies and had items that were worded differently or used different response options. For example, OOP measurements varied across studies and included costs associated with both direct medical services (eg, inpatient and outpatient services, mental health services, counseling, and medication) and direct nonmedical costs (eg, transportation, restaurant meals, cleaning, insurance premium increases, home maintenance, and child care). Some studies compared OOP costs to family income, whereas others only reported absolute levels of OOP costs. Finally, the reference period for evaluating OOP costs ranged from one month to a calendar year to a monthly average from the past two years. (51) .
Material Condition Measures of Financial Hardship
Four studies (29, 30, 35, 42) reported the proportion of cancer survivors whose OOP costs were greater than 20% of their annual income, with estimates between about 11% in a nationally representative population of cancer survivors of all ages (29) and 28% of Medicare beneficiaries with cancer (35) . The majority of studies' findings underscored the higher OOP costs among individuals diagnosed with cancer compared with those without a cancer history.
Indirect costs/productivity loss and patient time costs. Indirect costs/productivity loss were reported in 18 studies (40%) (6) (7) (8) (9) 28, 32, 34, 37, 40, 41, 43, 46, 51, 55, 59, 60, 61, 62) . As shown in Table 3 , studies measured indirect costs/productivity loss as loss of income, missed or lost days from work because of illness (ie, absenteeism, short-and long-term disability, days spent in bed), patient time costs (7%, n ¼ 3) (46, 60, 62) , and limitations in ability to do activities related to work and outside of work. Mean annual indirect cost ranged from $380 in a sample of prostate cancer survivors (year of dollars not stated) (46) (41) , the only study to assess lost productivity explicitly in adult survivors of childhood cancers, reported an annual per capita lost productivity of $4564 (2011 US dollars) in a nationally representative sample (2008 to 2011 data), approximately double the lost productivity of adults without a history of cancer during the same time period ($2314).
Medical debt, depletion of assets, and bankruptcy. Twelve studies reported medical debt, depletion of assets, or bankruptcy because of cancer (8, 9, 12, 23, 31, 43, 44, 50, 54, 56, 58, 63) (Table 4) . Bankruptcy claims ranged from 2% to 3% in the two years after diagnosis (9) . Furthermore, Ramsey et al. (12) found that cancer survivors in Western Washington State were 2.65 times more likely to file for bankruptcy than those without cancer and that younger survivors (ie, <40 years of age) had higher rates of bankruptcy than their older counterparts based on cancer surveillance data collected from 1995 to 2009. Meneses et al. (9) found that 12% of survivors borrowed money to pay for their medical expenses and 24% used up savings over a six-month period (data years not listed). Jagsi et al. (8) provided details regarding how the survivors financed their medical expenses-80% used income or savings, 10% increased credit card debt, and 7% borrowed from family or friends (2005 to 2007 data). In addition, several studies noted that survivors had trouble paying for medical bills and basic necessities (ie, utilities, mortgage, food, clothes) (8, 23, 43, 44, 50, 54, 56, 58, 63) . The study by Regenbogen et al. (54) reported that from 2011 to 2013 colorectal cancer survivors with complications were more likely to spend savings and borrow or take loans than survivors without complications (40% vs 31% and 18% vs 11%, respectively). Shankaran et al. (56) reported that 62% of colorectal cancer survivors were in debt, with a mean amount of $26 860 (2009 US dollars, 2008 to 2010 data), and Veenstra et al. (58) reported that a total of 34% of colorectal cancer survey respondents used savings and 13% had to borrow money or take out a loan as a result of their cancer treatment (2011 to 2013 data).
Psychological Response Measures of Financial Hardship
Three studies (33, 38, 54) included psychological response measures of financial hardship (eg, measures of distress, stress, and worry) ( Table 5) . A longitudinal study conducted by Ell et al. (38) among low-income women undergoing treatment or follow-up for breast/gynecological cancer found that 68% of cancer survivors had medical cost concerns, 47% had wage concerns, and 49% had financial stress; furthermore, those survivors who reported medical cost concerns, wage worry, or financial stress had poorer functional, emotional, and physical well-being, as well as a greater risk of depression (data years not listed). A multiregional study by Chino et al. (33) reported a total of 47% of cancer survivors experienced high levels of financial distress associated with dissatisfaction with general aspects of health 
Coping Behavior Measures of Financial Hardship
Seven studies included coping behavior measures of financial hardship (8, 10, 14, 23, 43, 44, 64) (Table 5 ). Examples of coping behavioral measures include treatment nonadherence and forgoing/delaying cancer-related and non-cancer-related medical care because of cost. Many studies highlight a negative effect on behavior, such that survivors with higher levels of financial hardship are at greater risk of treatment nonadherence and delaying or forgoing medical care (14, 23, 64) . Among specific financial sacrifices and cost-coping strategies of cancer survivors faced with financial hardship, several national and multistate studies evaluated general populations of cancer survivors and found that between 4% to 45% of survivors either skip, take less, or avoid filling prescription medication (8, 14, 23, 64) , and 5% to 20% reduce spending on both non-cancer-related health care or health care of other family members (14,44). (54) measured financial burden (score range ¼ 0-7, with higher scores denoting increased financial burden) by summing responses to seven statements: "I had to use savings," "I had to borrow money or take out a loan," "I could not make payments on credit cards or other bills," "I cut down on spending for food and/or clothes," "I cut down on spending for health care for other family members," "I cut down on recreational activities," and "I cut down on expenses in general." Mean scores for colorectal cancer survivors with complications following surgery were statistically significantly greater than for survivors without complications in multivariable Poisson regression analyses with two-sided tests of significance (2.21 vs 1.69, P < .001).
Discussion
The continued rise in costs of cancer care in the United States over the past few decades (66) (67) (68) (69) , alongside practice and payment reform initiatives (69) (70) (71) (72) (73) , have driven the need for metrics to evaluate the financial hardship associated with cancer. In this systemic review, we identified and summarized the measures of financial hardship among US cancer survivors in the published literature. We found that the number of published studies addressing at least one aspect of financial hardship increased dramatically over the past 25 years, especially in 2013-2015, which accounts for over half of the published literature included in this review. The increasing number of studies coincides with the increasing costs of cancer care and reflects a rapidly evolving field focusing on the impact of the costs of cancer care for patients. In our review of the published literature, we observed substantial heterogeneity in both the methods employed and the terms used to describe financial hardship, including financial distress, financial stress, financial hardship, financial problem, financial toxicity, financial burden, economic burden, economic hardship, and financial impact. The noticeable overlap in definitions and inconsistency in terms and measures used across studies underscores the need for consistent use of terms and defining measures in order to maximize the value of evidence produced from studies on the financial Overall, 45% of survivors were nonadherent with medication because of cost; a total of 36% used at least 2 of the 4 coping strategies; prescription drug plan and older age were protective against nonadherence; unemployment was associated with increased odds of nonadherence *CI ¼ confidence interval; NHIS ¼ National Health Interview Survey; OR ¼ odds ratio; SEER ¼ Surveillance, Epidemiology, and End Results program. 
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hardship among cancer survivors and to ensure that interventions, policies, and programs developed based on the results of these studies are targeting the most relevant aspect of financial hardship for patients and their families. Previous studies have also highlighted the lack of conceptual clarity for the construct of financial hardship in cancer-related research (22) . In our review, we observed that studies rarely stated explicitly which of the following financial hardship domains the construct was attempting to capture: 1) the material conditions that arise from the increased OOP expenses and potentially lower income that results from the inability to work during/following cancer treatment, 2) the psychological response to the increase in household expenses that must now be managed as patients navigate cancer care, or 3) the coping behaviors that patients adopt to manage their medical care while experiencing increased household expenses during/following cancer care. Future research should be conducted to further refine this typology and the measurement of financial hardship to inform intervention development. To move this effort forward, we recommend future cancer care research that includes financial hardship measures to explicitly state whether the measure is attempting to capture the material conditions, psychological response, and/or coping behaviors of the financial hardship experience of the cancer patient.
Importantly, few studies of financial hardship in cancer research used validated measures or commented about the validation process. The most commonly used validated measures were the COST measure (20) and the InCharge Financial Distress/ Financial Well-Being Scale (65) . The nationally representative MEPS includes standard quality-of-life measures, and the 2016-2017 MEPS Experiences with Cancer survey, which is currently being fielded, includes many items about financial hardship, in addition to the Patient Reported Outcomes Measurement Information System (PROMIS) global measures. Further validation of financial hardship measures for the typology we propose in large samples across diverse populations will be important in future research.
Regardless of how financial hardship has been measured, the 25 years of published research illustrate that the experience of financial hardship across multiple domains is a common problem for cancer survivors. A study recently published in 2016 (after the timeframe for this review) reported that in a nationally representative sample of working-age cancer survivors approximately one in four reported ever having any material financial hardship and one in three reported psychological financial hardship (18) . Many more recently available therapies have price tags of more than $100 000 per year and are commonly used in combination with other therapies. As medical costs are increasingly shifted to patients through higher health insurance premiums, deductibles, and greater cost sharing, the ongoing surveillance of the multiple domains of financial hardship will be critical as cancer patients navigate treatment and survivorship. Appropriately targeted interventions will need to be developed to ensure such financial hardships do not negatively impact treatment-related outcomes (eg, survival). Our results indicate that material condition measures were, most often, considered objective indicators that provided information related to: 1) OOP costs-costs associated with both direct medical (eg, medication) and nonmedical (eg, transportation) needs; 2) indirect costs and productivity losscosts associated with the reduction in work (eg, loss of income), time, and activities (eg, work-related or usual daily activities) because of the occurrence of cancer; and 3) medical debt and bankruptcy-the economic consequences of financial hardship. However, it is important to note that there is a lack of consistency in measurement approaches and definitions; thus any meaningful comparisons across studies using material condition indicators of financial hardship are severely hampered.
The studies using psychological response measures of financial hardship aim to estimate both the subjective (eg, financial distress) and financial consequences of a cancer diagnosis. Further, these psychological response measures illustrate the different areas of a cancer patient's well-being (eg, emotional, functional, mental, and physical) that can be influenced when experiencing financial hardship (38, 54) . A better understanding of quality of life and patient-reported outcomes associated with the survivor's psychological response to financial hardship is warranted, especially given the need for evidence for efforts like the American Society of Clinical Oncology (ASCO) Value in Cancer Care Initiative, which aims to incorporate data on both patient cost and quality of life.
Use of coping behavior measures in reviewed studies highlights the cost-coping strategies resulting from the financial hardship of cancer, illustrating trade-offs between paying for basic life needs (eg, food and shelter) and spending on health care for cancer survivors as well as other family members by cutting back on health care use (eg, forgoing or skipping medication) (8, 14, 44, 58) . Increased knowledge about financial coping behaviors that families use to manage cancer care will be especially useful in developing interventions to improve adherence to recommended treatment.
Many researchers combined components of the three different aspects of financial hardship to create a composite or summary measure, with items summarized into a single score/unit (eg, combining used savings, borrowed money or took out a loan, missed bill payments [8, 23, 43, 44, 54] ). Although composite or summary measures can be useful for ranking the overall severity of financial hardship, one limitation in these approaches is the extent to which individual items are ordered or weighted. Moreover, the interpretation of the score and what action to take based on the score are unclear. For instance, do cancer survivors who must mortgage their homes have the same level of financial hardship as those who cut down on vacation expenses? Additionally, should the survivor's consumption preference and risk tolerance be considered when interpreting the financial hardship scores? The use of different questions and combinations of questions across studies to construct composite or summary measures also limits the validity across populations. Consequently, while composite or summary measures may be useful in studies that have several items associated with a specific dimension of financial hardship (eg, creating an overall score for a psychological response measure such as financial stress), the use of composite measures may not clearly highlight whether the hardship issue is related to the financial resources available, how the patient feels about their lack of financial resources, or an issue with managing the financial resources available.
How might financial hardship be incorporated in costeffectiveness and value frameworks when evaluating cancer control strategies? These frameworks offer transparent approaches to quantifying and summarizing the costs and benefits (or consequences) associated with alternative strategies, for use by health care programs, health plans, and other policy makers operating in settings with limited resources. Some of the material financial hardship measures we identified, such as patient OOP costs, are traditional measures of cost from the perspective of the patient and society, more broadly. Other material measures, such as productivity losses, may also be measured from the patient or societal perspective, yet represent areas of some controversy within the field. Nevertheless, these material financial hardship measures could be used as inputs in some cost effectiveness estimates, such as the incremental cost-effectiveness ratio (ICER), where the numerator is cost (eg, out-of-pocket costs because of particular intervention or treatment). Psychological financial hardship measures might be conceptualized as a component of patient utility, as part of the denominator of the ICER. Financial hardship concepts are important when considering the costs and benefits of different strategies and will be important for future cancer care research.
Although we included studies published over the past 25 years in this review of the published literature, we did not include studies of financial hardship in informal caregivers, including spouses and partners, siblings, parents, children, and friends of cancer survivors. The few studies that have been conducted suggest that caregivers also face considerable OOP costs (74) (75) (76) (77) and productivity losses (74-78) associated with cancer. They may also experience psychological distress and delay or forgo their own medical care as a behavioral response to financial hardship. Improving understanding of financial hardship for the entire household and support network will be an important area for additional research.
We limited our systematic review to studies conducted in the United States because of substantial differences between health systems in other countries and the United States. The majority of other developed countries have universal health insurance coverage, making the differences in health care delivery, particularly for the uninsured, quite distinct in the United States. Differences in health care systems between the United States and other developed countries also affect the insured with respect to health insurance premiums, deductibles, copayments, coinsurance, and limitations in coverage. Thus, the potential for very high OOP payments for cancer survivors is quite different in the United States than in other countries. Nonetheless, several studies have evaluated financial hardship outside of the United States (79) (80) (81) (82) (83) , and comparative studies in similar groups of patients will be important for future research for improving understanding of how differences in health systems can impact financial hardship.
An important strength of our systematic review is that we used a multiple database and keyword search strategy to identify articles related to financial hardship in cancer survivors over the past 25 years. However, despite the use of multiple databases and replicating each search strategy for each database, we were unable to capture every relevant article because of different indexing used by the databases and the inconsistent terminology used to define financial hardship. To help minimize this limitation, we hand-searched the reference lists for each article for any additional studies that were not captured in the initial electronic search process. The fact that we identified 10 studies with our hand-search reflects a lack of specificity with the financial hardship search terms available in major publication databases.
Data abstraction by a single author is another limitation to this review; however, we did our best to standardize the data abstraction process by using objective measures of financial hardship and multiple reviewers to resolve any disagreements or inconsistencies in the data. Yet, despite our efforts, there still may be some unavoidable subjectivity in classifying some of the measures. Finally, we included studies of financial hardship published over several decades and it is possible that estimates published in earlier years are not directly comparable with those published more recently. However, our synthesis of findings was qualitative, rather than quantitative. In addition, our exhaustive systematic review offers a comprehensive picture of an increasingly recognized issue of great importance to patients and a rapidly emerging area of research.
In summary, the complexity of measuring the financial hardship of cancer has led to substantial heterogeneity in methods and measures. Our findings highlight the need for consistent use of definitions, terms, and measures to better inform development of interventions in order to prevent and minimize the financial hardship experienced by cancer survivors.
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